• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Partnership to supercharge vaccine production

Bioengineer by Bioengineer
January 15, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: The University of Queensland


Vaccines to stop the world’s next epidemic could be developed in record time under a $14.7 million
partnership using technology developed at The University of Queensland.

The Coalition for Epidemic Preparedness Innovations (CEPI) has funded a research consortium to
develop a rapid response pipeline to develop and test new vaccines in as little as 16 weeks.

The Australia Government has been an early supporter of CEPI by providing a previous contribution
of $2 million, and UQ and CEPI are pleased to see a further contribution today of $4.5 million.

UQ’s Professor Paul Young and Dr Keith Chappell are leading the project, which has the potential to
save millions of lives by targeting existing and new pathogens.

“The World Health Organization’s Blueprint list of priority diseases recognises that new epidemics
can arise from known and unknown viruses – the latter referred to as ‘Disease X’,” Professor Young
said.

“These new and emerging pathogens have the potential to reach global epidemic levels.”

Dr Chappell said the project was ambitious, as more conventional approaches could take years or
even decades.

“We aim to be able to manufacture more than 200,000 doses of a new vaccine, demonstrate safety
and the likelihood of efficacy, and be ready for field deployment in as little as six months,” he said.

Professor Young, Dr Chappell and Dr Daniel Watterson have patented ‘molecular clamp’ technology
that provides stability to the viral proteins that are the primary target of our immune defence.

“The technology has been designed as a platform approach to generate vaccines against a range of
human and animal viruses,” Professor Young said.

“We’ve had some extremely promising results so far from trials targeting viruses such as influenza,
Ebola, Nipah and MERS coronavirus.”

Dr Watterson said the collaboration would act as an insurance policy against deadly outbreaks
caused by the emergence of viral epidemics or pandemics.

“By rapidly creating vaccines to these new threats, we’ll be able to quickly limit the spread of disease
and diffuse potentially catastrophic situations.

“Molecular clamp technology has the potential to address some of today’s most devastating
diseases and to fundamentally change how we protect ourselves from common diseases.”

###

The collaboration involves UQ, the CSIRO, the World Health Organization’s Collaborating Centre for
Reference and Research on Influenza (WHO-CC), the Australian National University (ANU), Hong
Kong University (HKU) and Q-Pharm Pty Ltd.

The technology has been patented by UniQuest, UQ’s commercialisation company.

Images, summarised information about the technology and CEPI’s extended release are available
via this Dropbox: https://www.dropbox.com/sh/isq20pg3r8nd6xr/AACgthVrwNAiWSNCoZQxz9xpa?dl=0

Media Contact
Prof Paul Young
p.young@uq.edu.au
61-423-565-446

Tags: EpidemiologyImmunology/Allergies/AsthmaMedicine/HealthPublic HealthVaccines
Share12Tweet8Share2ShareShareShare2

Related Posts

Cardiac Tamponade from Effusive Constrictive Pericarditis Arises in Common Variable Immunodeficiency

Cardiac Tamponade from Effusive Constrictive Pericarditis Arises in Common Variable Immunodeficiency

November 19, 2026
Survey Details Widespread Reflexive Blood Culturing in UK and Irish Paediatric ICUs

Survey Details Widespread Reflexive Blood Culturing in UK and Irish Paediatric ICUs

November 19, 2026

Pharmacist Assessment Clarifies Muscle Enzyme Surge in Late-Onset Mania Case

November 19, 2026

South African Master of Public Health Degrees Transition Alumni into Health Leadership

November 19, 2026
Please login to join discussion

POPULAR NEWS

  • Study Reveals Outflow of Early-Career Japanese Pharmacists From Hospitals to Pharmacies

    Study Reveals Outflow of Early-Career Japanese Pharmacists From Hospitals to Pharmacies

    29 shares
    Share 12 Tweet 7
  • Mouse and Human Studies Show GATA2 Actively Maintains Müllerian Ducts

    29 shares
    Share 12 Tweet 7
  • Study Identifies Factors Linked to Women’s Health Decision Autonomy in Zambia

    29 shares
    Share 12 Tweet 7
  • Dual-Network Decomposition Model Improves Carbon Price Prediction Intervals Across Chinese Markets

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Restrained Shrinkage in Ultra-High Performance Concrete Depends on Interface and Layer Thickness

Interpretable Deep Learning Diagnoses Paddy Crop Diseases and Flags Uncertain Cases

Cardiac Tamponade from Effusive Constrictive Pericarditis Arises in Common Variable Immunodeficiency

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.